Comparative studies on the anticancer activity of colchicine by various controlled drug delivery modes

International Journal of Pharma and Bio Sciences

Volumn 4, Issue 1, 2013, Pages 9-26

  Balasubramanian, E ^a   Gajendran, T ^a  

^a ANNA UNIVERSITY   (India)

Author keywords

Colchicine; Controlled drug delivery; Cytotoxicity analysis

Indexed keywords

ANTINEOPLASTIC AGENT; COLCHICINE; COLCHICUM AUTUMNALE EXTRACT; DRUG CARRIER; ETHOSOME; LIPOSOME; NIOSOME; PLANT EXTRACT; PRONIOSOME; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRAIN MCF 7; CELL VIABILITY; COLCHICUM; COLCHICUM AUTUMNALE; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG IDENTIFICATION; DRUG SYNTHESIS; IC 50; IN VITRO STUDY; INFRARED SPECTROSCOPY; PARTICLE SIZE; PLANT SEED; MCF 7 CELL LINE;

COLCHICUM; COLCHICUM AUTUMNALE;

EID: 84879643345     PISSN: None     EISSN: 09756299     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Lange U, Schumann C, Schmidt KL. Current aspects of colchicine therapy. Classical indications and new therapeutic uses. Eur J Med Res 2001;6:150-60.
2. Molad Y. Update on colchicine and its mechanism of action. Curr Rheumatol Rep 2002;3:252-6.
3. Biju, SS; Talegaonkar, S; Mishra, PR and Khar, RK (2006), "Vesicular Systems: An Overview", Indian Journal of Pharmaceutical Sciences, 68(2), 141-153
4. Vyas, SP and Khar, RK (2004), "Targeted and Controlled Drug Delivery, Novel Carrier Systems", First Reprint, CBS Publishers & Distributors, New Delhi, 39.
5. Fordham JN, Kirwan J, Cason J, Currey HL. Prolonged reduction in polymorphonucler adhesion following oral colchicine. Ann Rheum Dis 1981;40:605-8.
6. Ferron GM, Rochdi M, Jusko WJ, Scherrmann JM. Oral absorption characteristics and pharmacokinetics of colchicine in healthy volunteers after single multiple doses. J Clin Pharmacol 1996;36:874-83.
7. Rochdi M, Sabouraud A, Girre V, Venet R, Schermann JM. Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects. Eur J Clin Pharmacol 1994;46:351-4.
8. Tateishi T, Soucek P, Caraco Y, Guencerich FP, Wood AJ. Colchicine biotransformation by human livermicrosomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation. Biochem Pharmacol 1997;53:111-6.
9. Dvorak Z, Modriansky M, Pichard-Garcia L, Balaguer P, Vilarem MJ, UlrichováJ et al. Colchicine down-regulates cytochrome P450, 2B6, 2C8, 2C9, and 3A4 in human hepatocytes by affecting their glucocorticoid receptor-mediated regulation.Mol Pharmacol 2003;64:160-9.
10. Leighton JA, Bay MK, Maldonado AL, Schenker S, Speeg KV. Colchicine clearance is impaired in alcoholic cirrhosis. Hepatology 1991;14:1013-5.
11. Rudi J, Raedsch R, Gerteis C, Schlenker T, Plachlky J, Walter-Sack I, et al. Plasma kinetics and biliary excretion of colchicine in patients with chronic liver disease after oral administration of a single dose and after long-term treatment. Scand J Gastroenterol 1994;14:1013-5.
12. Speeg KV. Effect of cyclosporine on colchicine secretion by the kidney multidrug transported studied in vivo. Pharmacology 1992;261:50-5.
13. Ben-Chetrit E, Schermann JM, Levy M. Colchicine in breast milk of patients with familial Mediterranean fever. Arthritis Rheum 1996;39:1213-7.
14. Lidar M, Livneh A. Familial Mediterranean fever: clinical, molecular and management advancements. Netherlands J Med 2007;65:318-24.
15. Maisch B, Seferovic PM, Ristic AD, Erbel R, Rienmüller R, Adler Y, et al. Task Force on the diagnosis management of pericardial disease of the European Society of Cardiology. Guidelines on the Diagnosis and management of pericardial diseases Eur Heart J 2004;25:587-610.
16. Imazio M, Demichelis B, Parrini I, Cecchi E, Demarie G, Ghisio A, et al. Management, risk factors, and outcomes in recurrent pericarditis. Am J Cardio 2005;96:736-9.
17. Sussman JS, Brozena SSC, Skop N, Korecka M, Shaw LM. Accidental intravenous colchicine poisoning. Ther Drug Monit 2004;26:688-92.
18. Centers for Disease Control and Prevention (CDC. Deaths from intravenous colchicine resulting from a compounding pharmacy error - Oregon and Washington, 2007. MMWR Morb Mortal Wkly Rep 2007, 56; 2007. p. 1050-2.
19. Riley K. FDA approves colchicine for acute gout, Mediterranean fever. Agency also provides new information to physicians regarding safe use of drug. Media Inquiries 2009;301:796-4674 Consumers Inquiries 888-INFO-FDA.
20. Kesselheim AS, Solomon DH. Incentives for drug development - the curious case of colchicine. New Engl J Med 2010;362:2045-8.
21. Ben-Chetrit E, Levy M. Colchicine prophylaxis in familial Mediterranean fever: reappraisal after 15 years. Semin Arthritis Rheum 1991;20:241-6.
22. Yurdakui S, Tuzun CMY, Ozyzgan Y, Hamuryudan V, Senocak OM, Yazici H. A double-blind trial of colchicine in Behçet's syndrome. Arthritis Rheum 2001;44:2686-92.
23. Zemer D, Livneh A, Danon YL, Pras M, Sohar E. Long term colchicine treatment in children with familial Mediterranean fever. Arthritis Rheum 1991:34973-7.
24. Nakamura A, Matsuda M, Tazakawa K, Shimojima Y, Ikeda S. Successful with infliximab and low-dose methotrexate in a Japanese patient with familia Mediterranean fever. Intern Med 2007;46:1247-9.
25. Aikawa NE, Gonçalves, Silva CA, Gonçalves C, BonfáE, de Carvalho JF. Late response to anti-TNF-alpha therapy in refractory mucocutaneous lesions of Behçet's disease; Dec 11 2009 [Epub ahead of print].
26. Alpay N, Sumnu A, Caliskan Y, Yazici H, Türkmen A, Gül A. Efficacy of anakinra treatment in a patient with colchicineresistant familial Mediterranean fever. Rheumatol Int Apr 13 2010, doi:10.1007/00296-010-1474-6.
27. Goldkind SF, Sahin L, Gallauresi B. Enrolling pregnant women in research - lessons from the H1N1 influenza pandemic. New Engl J Med 2010;362:2241-3.
28. Douglas G, King B. Colchicine inhibits human trophoblasts differentiation in vitro.Placenta 1993;14:187-201.
29. Rabinovitch O, Zemer D, Kukia E, Sohar E, Mashiach S. Colchicine treatment in conception and pregnancy: two hundred thirty-one pregnancies in patients with familial Mediterranean fever. Am J Reprod Immunol 1992;28:245-6.
30. Adler Y, Finkelstein Y, Guindo J, Rodrigues de la Serna AM, Schoenfeld Y, Bayes Genis A, et al. Colchicine treatment for recurrent pericarditis. A decade of experience. Circulation 1998;97:2183-5.
31. Iacobuzio-Donahue CA, Lee EL, Abraham SC, Yardley JH, Wu TT. Colchicine toxicity: distinct morphologic findings in gastrointestinal biopsies. Am J Surg Pathol 2001;25:1067-73.
32. Al-Darajj WI, Al-Mahmoud RM, Ilvas M. Gastric changes following colchicines therapy in patients with FMF. Dig Dis Sci 2008;53:2079-82.
33. Baker SK, Goodwin S, Sur M, Tarnoposky MA. Cytoskeletal myotoxicity from simvastatin and colchicine. Clin Neuropharmacol 2002;25:266-8.
34. Satturwar, PM; Fulzele, SV; Nande, NS and Khandare, JN (2002), "Formulation and evaluation of ketoconazole niosomes", Indian Journal of Pharmaceutical Sciences, Vol.64, 155-8.
35. Niel E, Shermann JM. Colchicine today. Joint Bone Spine 2006;73:672-8..
36. Van Winden ECA, Zuidam NJ, Crommelin DJA. Strategies for large scale production and optimized stability of pharmaceutical liposomes developed for parenteral use. In: Lasic DD, Papahadjopoulos D, eds. Medical Applications of Liposomes. Amsterdam: Elsevier; 1998:567-604.
37. Shahiwala, A and Misra, A (2002), "Studies in topical application of niosomally entrapped nimesulide", J. Pharm. Sci., 5 (3), 220-225.
38. Sheena, IP; Singh, UV; Kamath, R; Umadevi, P and Udupa, N (1998), "Niosomal withaferin with better antitumor efficacy", Indian Journal of Pharm. Sciences, 60 (1),45-48.
39. "Indian Pharmacopoeia" (1996), Govt. of India, Ministry of Health & Family Welfare, 4th Ed., Vol. II, A-144.
40. Florey, K (2001), "Analytical Profile of Drug Substances and Exicipients", Academic Press, Milliford, New Jersey, 28,199-240.
41. Azmin, MN; Florence, AT; Handajani, VR; Stuart, JFB; Vanlerberghe, G and Wittakar, JS (1985), "The effect of nonionic surfactant vesicle (niosome) entrapment on the absorption and distribution of methotrexate in mice", J. Pharm. Pharmacol., 37,237-242.
42. Deamer, D and Bhangham, AD (1976), "Biochem. Biphys. Acta, 443, 629-634.
43. Yekta Ozer, Atilla Hinal A; Bouwstra, Joke A (1991) Eur. J. Pharm. Biopharm., 37(2), 75-79.
44. Ruckmani, K; Jayakar, B and Ghosal, SK (2000), "Non-ionic Surfactant Vesicles of Cytarabine HCl for Effective Treatment of Leukemias", Drug Development and Industrial Pharmacy, 26(2), 217-222.
45. Wan, LSC and Lee, PFS (1974), Can. J. Pharm. Sci., 9, 82.
46. Kulkarni, SB; Betageri, GV and Singh, M (1995), "Factors affecting microencapsulation of drugs in liposomes", Jour. of Microencapsulation, 12, 229-246.
47. Uchegbu IF, Vyas SP. Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm. 1998;172:33-70.
48. Uchegbu IF, ed. Synthetic Surfactant Vesicles: Niosomes and Other Non- Phospholipid Vesicular Systems, Drug Targeting and Delivery, Volume 11. Amsterdam: Harwood Academic Publishers; 2000.
49. Arunothayanun P, Turton JA, Uchegbu IF, Florence AT. Preparation and in vitro/in vivo evaluation of luteinizing hormone releasing hormone (LHRH) loaded polyhedral and spherical/tubular niosomes. J Pharm Sci. 1999;88(1):34
50. Kristmundsdottir T, Gudmundsson OS, Ingvarsdottir K. Release of Diltiazem from Eudragit microparticles prepared by spray drying.Int J Pharm. 137:159-65 (1996).
51. gowda.DV,khan MS, nagandra Rspary dried indapamide microparticle for controlled release -a novel approach. International Journal of Pharma and Bio Sciences, Vol.1/Issue-4/Oct-Dec.2010
52. Hu C, Rhodes DG. Proniosomes: a novel drug carrier preparation. Int Pharm. 1999;185(1):23-35.